Abstract 5204
Background
Microbiota has been linked to the development of multiple cancers through various mechanisms. In bladder cancer (BC), preliminary studies have found alterations in the urinary microbiota of patients with urothelial carcinoma in comparison with healthy individuals. However, the bladder microbiota (BMi) has not been explored. The aims of this study were to characterize the BMi in a cohort of BC patients, to explore differences in the BMi composition between tumor (T) and normal (N) mucosa, and to identify its correlation with clinicopathologic features.
Methods
A total of 58 samples obtained by cystectomy from 32 BC patients (frozen tumor tissues and normal appearing mucosa for 26 patients and 6 tumor tissues) from Hospital General de Elche Biobank (Spain) were included. DNAs isolated from bladder samples were used to perform 16S rRNA gene sequencing (V3 and V4 region). A paired-end 2 × 300 bp cycle run on Illumina MiSeq. Ribosomal Database Project Classifier was used for taxonomical assignment. Statistical analysis was performed using Rstudio platform. Groups of data were compared using Wilcoxon test and Mann Whitney test for 26T vs 26N (paired group) and 32T vs 26N (unpaired group), respectively.
Results
There were no statistically significant differences of diversity between T and N, but there were differences of richness between T and N at the genus level (Chao1 index, p = 0.049). Globally, the most abundant phylum was Firmicutes, followed by Bacteroidetes, Proteobacteria and Actinobacteria. We found that the microbial composition differed significantly between T and N in both groups. At the phylum level, while Cyanobacteria.Chloroplast (0.74% vs 2.44%; p = 0.025) was enriched in T, Actinobacteria were reduced in T. Principal component analysis based on the relative abundance of phylum (36.9% PC1 and 28.7% PC2 of explained variance) revealed a significant separation in bacterial community composition between tumor tissues associated with histological tumor grade (permanova grade =0.036).
Conclusions
Significant differences in the BMi composition associated with tumor grade were observed. Additional studies are needed to determine the role of BMi in the evolution of BC and its therapeutic implications.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3140 - Phase 2 study of olaparib in previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) or homologous recombination repair deficiency (HRD): LYNK-002
Presenter: David Hyman
Session: Poster Display session 3
Resources:
Abstract
2655 - The K-BASKET trial: A prospective phase II biomarker-driven multiple basket trial in Korean solid cancer patients.
Presenter: Seul Kim
Session: Poster Display session 3
Resources:
Abstract
5938 - Cambridge Liquid biopsy “CALIBRATION” study: Can changes in circulating tumour DNA (ctDNA) predict durable tumour responses in patients with advanced oesophageal cancer receiving MEDI4736?
Presenter: Constanza Linossi
Session: Poster Display session 3
Resources:
Abstract
3799 - Validation of a tumour mutational burden workflow on routine histological samples of colorectal cancer and assessment of a cohort with synchronous hepatic metastases
Presenter: Andrea Mafficini
Session: Poster Display session 3
Resources:
Abstract
4647 - Microsatellite Instability Testing and Lynch Syndrome Screening For Colorectal Cancer Patients Through Tumor Sequencing
Presenter: Li Liu
Session: Poster Display session 3
Resources:
Abstract
3231 - "Liquid Withdarw" technique in CT-guided cutting needle lung biopsy: decreased incidence of complications and increased tissue amount for lung cancer molecular testing.
Presenter: Xue Wang
Session: Poster Display session 3
Resources:
Abstract
3282 - WGS Implementation in standard cancer Diagnostics for Every cancer patient (WIDE)
Presenter: Paul Roepman
Session: Poster Display session 3
Resources:
Abstract
5905 - Known and unknown gene fusion detection capabilities of solid tumor laboratories conducting next generation sequencing in 6 countries
Presenter: Steph Finucane
Session: Poster Display session 3
Resources:
Abstract
4238 - Clinical and Analytical Accuracy of a 523 Gene Panel Next-Generation Sequencing (NGS) Assay on Formalin-Fixed Paraffin-Embedded (FFPE) Solid Tumor Samples
Presenter: Ina Deras
Session: Poster Display session 3
Resources:
Abstract
2493 - Methylation analysis of MLH1 using droplet digital PCR and methylation sensitive restriction enzyme.
Presenter: Celine De Rop
Session: Poster Display session 3
Resources:
Abstract